Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 29;10(5):702. doi: 10.3390/vaccines10050702

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Cross-neutralizing activities of the B.1.1.7 monovalent, B.1.351 monovalent and SCTV01C bivalent vaccines against SARS-CoV-2 pseudovirus (PsV) based on D614G, VOCs, VOIs, VUMs and other variants. (A) Scheme of immunization and serum collection. C57BL/6J mice (n = 8/group) were immunized with B.1.1.7 monovalent vaccine (1 μg/dose), B.1.351 monovalent vaccine (1 μg/dose), or SCTV01C (1 μg/dose for each antigen) on days 0 and 14. Inhibition of PsV infection by serially diluted mouse sera were analyzed on day 21. (B) Neutralizing antibody titers against each variant lineage were analyzed. The results are representative of two independent experiments. Dotted line defines the limit of detection (represented as a GMT of 60). VOC, variants of concern; VOI, variants of interest. Vac is an abbreviation for Vaccine. Bars show GMT ± SD. Data were log transformed and analyzed by Student’s t test (unpaired, two-tailed).